Ian A.J. Lorimer

1.9k citations

41 papers · 1.3k indexed · h-index 21

Impact in

Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism
- Cancer, Lipids, and Metabolism
Oncology top 5%
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research

Papers in

Oncology 17
- Colorectal Cancer Treatments and Studies 5
- HER2/EGFR in Cancer Research 4
- Cancer-related Molecular Pathways 4
Cancer Research 9
- Cancer, Lipids, and Metabolism 4

Co-authors: D A E Parolin Jim Dimitroulakos Glenwood D. Goss R. Mitchell Baldwin Jennifer Hanson Manijeh Daneshmand B. D. Sanwal Karim Mekhail
Journals: Journal of Biological Chemistry (4 papers)Clinical Cancer Research (3 papers)Oncotarget (3 papers)Oncogene (3 papers)Current Cancer Drug Targets (2 papers)
Partner nations: Canada United States Australia

In The Last Decade

Ian A.J. Lorimer

41 papers receiving 1.3k citations

Peers

Countries citing papers authored by Ian A.J. Lorimer

Since Specialization

Citations

This map shows the geographic impact of Ian A.J. Lorimer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian A.J. Lorimer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian A.J. Lorimer more than expected).

Fields of papers citing papers by Ian A.J. Lorimer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian A.J. Lorimer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian A.J. Lorimer. The network helps show where Ian A.J. Lorimer may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Ian A.J. Lorimer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ian A.J. Lorimer Line = papers co-authored together Ian A.J. Lorimer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Transglutaminase 2 function in glioblastoma tumor efferocytosis Cell Death and Disease ·侃渡邊, Chen Yuzho, J. Z. Wang, David G. Muñoz, Jeffrey W. Keillor, John Sinclair, 有田愛子, C. Martin, John Woulfe, Ian A.J. Lorimer	2025	1
2	Potential roles for efferocytosis in glioblastoma immune evasion Neuro-Oncology Advances ·Ian A.J. Lorimer	2024	2
3	Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy Molecular Therapy ·Boaz Wong, Arlen Chung, Boris Afanas'evich Eder, Lina Rahmawati, 차유림, 苗欣, Daniel Serrano, S. Ulizko, Abid Faten Fatima Zohra, Zaid Taha, Mabihah Liyana Salan, Andrew Chen, Ian A.J. Lorimer, Barbara C. Vanderhyden, Rozanne Arulanandam, Jean‐Simon Diallo	2023	11
4	Identification of Rac guanine nucleotide exchange factors promoting Lgl1 phosphorylation in glioblastoma Journal of Biological Chemistry ·政也矢島, Eva Soltes, Н.Н. Старцева, Karen Jardine, David P. Cook, Ian A.J. Lorimer	2021	1
5	Engineered cells as glioblastoma therapeutics Cancer Gene Therapy ·輝彦吉田, Ian A.J. Lorimer	2021	12
6	Induction of senescence in primary glioblastoma cells by serum and TGFβ Scientific Reports ·Ritesh Kumar, Н.Н. Старцева, Theodore J. Perkins, Jennifer Hanson, Ian A.J. Lorimer	2017	17
7	Engineering PTEN-L for Cell-Mediated Delivery Molecular Therapy — Methods & Clinical Development ·政也矢島, Н.Н. Старцева, Lisa M. Julian, William L. Stanford, Caitlyn Vlasschaert, Douglas A. Gray, Eva Soltes, Ian A.J. Lorimer	2017	11
8	Control of glioblastoma tumorigenesis by feed-forward cytokine signaling Nature Neuroscience ·Arezu Jahani‐Asl, Hang Yin, Vahab D. Soleimani, Takrima Haque, H. Artee Luchman, Natasha C. Chang, Marie‐Claude Sincennes, Sidharth V. Puram, Andrew M. Scott, Ian A.J. Lorimer, Theodore J. Perkins, Keith L. Ligon, Samuel Weiss, Michael A. Rudnicki, Azad Bonni	2016	74
9	PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17 Clinical Cancer Research ·Christos S. Karapetis, Derek J. Jonker, Manijeh Daneshmand, Jennifer Hanson, Christopher J. O’Callaghan, Celia Marginean, John Zalcberg, John Simes, Malcolm J. Moore, Niall C. Tebbutt, Timothy Price, Jeremy Shapiro, Nick Pavlakis, Peter Gibbs, Guy A. Van Hazel, M. Strauss, Rashida Haq, Shakeel Virk, Dongsheng Tu, Ian A.J. Lorimer	2013	128
10	BRAF, PIK3CA, and PTEN status and benefit from cetuximab (CET) in the treatment of advanced colorectal cancer (CRC): Results from NCIC CTG/AGITG CO.17. Journal of Clinical Oncology ·Derek J. Jonker, Christos S. Karapetis, Christopher J. O’Callaghan, Celia Marginean, John Zalcberg, John Simes, Malcolm J. Moore, Niall C. Tebbutt, Timothy Price, Manijeh Daneshmand, Jennifer Hanson, Jeremy Shapiro, Nick Pavlakis, Peter Gibbs, Guy A. Van Hazel, S Nebelung, Rashida Haq, Shakeel Virk, Dongsheng Tu, Ian A.J. Lorimer	2012	2
11	Coordination of glioblastoma cell motility by PKCι Molecular Cancer ·R. Mitchell Baldwin, H. Hotaka, D A E Parolin, Jana Gillies, А Т Калимуллин, 政也矢島, Douglas A. Gray, Ian A.J. Lorimer	2010	20
12	Induction of Premature Senescence by Hsp90 Inhibition in Small Cell Lung Cancer PLoS ONE ·Ian J. Restall, Ian A.J. Lorimer	2010	20
13	Regulation of glioblastoma cell invasion by PKCι and RhoB Oncogene ·R. Mitchell Baldwin, D A E Parolin, Ian A.J. Lorimer	2008	47
14	Activation of p38MAPK Contributes to Expanded Polyglutamine-Induced Cytotoxicity PLoS ONE ·Alejandra Díaz Calderón, R. Mitchell Baldwin, Matthew Y. H. Tang, Ian A.J. Lorimer, Douglas A. Gray	2008	11
15	Protection of glioblastoma cells from cisplatin cytotoxicity via protein kinase Cι-mediated attenuation of p38 MAP kinase signaling Oncogene ·R. Mitchell Baldwin, J. van Dalen, D A E Parolin, Paul M. Krzyzanowski, Miguel A. Andrade‐Navarro, Ian A.J. Lorimer	2005	55
16	A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer Investigational New Drugs ·Mary J. MacKenzie, Holger W. Hirte, Brazil Reginaldo P, R. Jaroszynski, Rakesh Goel, Pierre Major, Wilson H. Miller, Lawrence Panasci, Ian A.J. Lorimer, Gerald Batist, S. Matthews, Maria Eduarda Bueno Tallevi, Lesley Seymour	2005	56
17	Hypoxia Inducible Factor Activates the Transforming Growth Factor-α/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma Cells Journal of Biological Chemistry ·Lakshman Gunaratnam, Anne T. McDaid, Aleksandra Franovic, K. Olson, Karim Mekhail, D A E Parolin, Eijiro Nakamura, Ian A.J. Lorimer, Stephen Lee	2003	150
18	Interaction of Hsp90 with the Nascent Form of the Mutant Epidermal Growth Factor Receptor EGFRvIII Journal of Biological Chemistry ·政也矢島, D A E Parolin, A. I. Sadykova, John F. Kelly, Ian A.J. Lorimer	2003	58
19	Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells Journal of Cancer Research and Clinical Oncology ·WJ Swiatecki, Claudia Cristal, Nima Niknejad, Glenwood D. Goss, Ian A.J. Lorimer, Jim Dimitroulakos	2003	28
20	Mutant Epidermal Growth Factor Receptors as Targets for Cancer Therapy Current Cancer Drug Targets ·Ian A.J. Lorimer	2002	56

About Ian A.J. Lorimer

Ian A.J. Lorimer is a scholar working on Oncology, Cancer Research, Molecular Biology, Cell Biology and Pathology and Forensic Medicine, having authored 41 papers that have together received 1.3k indexed citations. Recurring topics across this work include Protein Kinase Regulation and GTPase Signaling (7 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Colorectal Cancer Treatments and Studies (5 papers), Microtubule and mitosis dynamics (4 papers), HER2/EGFR in Cancer Research (4 papers), Cancer-related Molecular Pathways (4 papers), Telomeres, Telomerase, and Senescence (4 papers) and Cancer, Lipids, and Metabolism (4 papers). The work is most often cited by research in Cancer Research (399 citations), Oncology (518 citations), Genetics (134 citations), Molecular Biology (710 citations) and Pulmonary and Respiratory Medicine (308 citations). Ian A.J. Lorimer has collaborated with scholars based in Canada, United States and Australia. Frequent co-authors include D A E Parolin, Jim Dimitroulakos, Glenwood D. Goss, R. Mitchell Baldwin, Jennifer Hanson, Manijeh Daneshmand, B. D. Sanwal, Karim Mekhail, Eijiro Nakamura and Aleksandra Franovic. Their work appears in journals such as Journal of Biological Chemistry, Clinical Cancer Research, Oncotarget, Oncogene and Current Cancer Drug Targets.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact